HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
FANCA
FA complementation group A
Chromosome 16 Β· 16q24.3
NCBI Gene: 2175Ensembl: ENSG00000187741.16HGNC: HGNC:3582UniProt: O15360
238PubMed Papers
21Diseases
0Drugs
982Pathogenic Variants
FUNCTIONAL ROLE
DNA RepairHub Gene
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingchromatinnucleusnucleoplasmFanconi anemia complementation group AFanconi anemiaacute myeloid leukemiamyelodysplastic syndrome
✦AI Summary

FANCA encodes a DNA repair protein essential for interstrand cross-link (ICL) repair and maintenance of chromosome 16 1. As a core component of the Fanconi anemia (FA) nuclear complex, FANCA functions in postreplication repair and cell cycle checkpoint control, with all pathogenic missense mutations preventing nuclear localization and FA/BRCA pathway activation 1. Mutations in FANCA cause Fanconi anemia, an autosomal recessive disorder characterized by congenital abnormalities, progressive bone marrow failure, and marked cancer predisposition 2. FANCA accounts for approximately 58% of FA cases in some populations and represents the most commonly mutated complementation group 2. The disease manifests with skeletal and skin deformities, hematologic complications including pancytopenia, and cancer susceptibility, with splicing or deletion mutations generally causing more severe phenotypes than missense variants 3. Beyond classical FA presentation, FANCA mutations have been identified in primary ovarian insufficiency cases, suggesting broader roles in meiosis and reproductive function 4. Molecular characterization reveals extensive allelic heterogeneity with both recurrent and population-specific mutations, complicating genetic diagnosis but essential for accurate genotype-phenotype correlation and clinical management 5.

Sources cited
1
FANCA functions in DNA repair, interstrand cross-link repair, and chromosome stability; pathogenic missense mutations prevent nuclear localization and FA/BRCA pathway activation
PMID: 21273304
2
FANCA mutations account for ~58% of FA cases; FA characterized by congenital abnormalities, bone marrow failure, and malignancy predisposition
PMID: 30792206
3
FA-A is most common FA subtype; splicing/deletion mutations cause more severe disease than missense mutations; describes clinical manifestations including deformities and blood system diseases
PMID: 36463940
4
FANCA linked to primary ovarian insufficiency, implicated in meiosis/DNA repair pathways
PMID: 34794894
5
FANCA shows extensive allelic heterogeneity with high heterogeneity of mutation combinations; describes functional assays for pathogenicity determination
PMID: 29098742
Disease Associationsβ“˜21
Fanconi anemia complementation group AOpen Targets
0.85Strong
Fanconi anemiaOpen Targets
0.78Strong
acute myeloid leukemiaOpen Targets
0.54Moderate
myelodysplastic syndromeOpen Targets
0.48Moderate
leukemiaOpen Targets
0.47Moderate
Abnormality of skin pigmentationOpen Targets
0.46Moderate
Menkes diseaseOpen Targets
0.46Moderate
genetic disorderOpen Targets
0.45Moderate
Abnormality of blood and blood-forming tissuesOpen Targets
0.41Moderate
head and neck squamous cell carcinomaOpen Targets
0.39Weak
ovarian cancerOpen Targets
0.39Weak
gastric carcinomaOpen Targets
0.38Weak
skin basal cell carcinomaOpen Targets
0.38Weak
head and neck malignant neoplasiaOpen Targets
0.38Weak
lung carcinomaOpen Targets
0.37Weak
prostate carcinomaOpen Targets
0.37Weak
hair colorOpen Targets
0.37Weak
hearing lossOpen Targets
0.37Weak
Bone marrow hypocellularityOpen Targets
0.37Weak
hereditary neoplastic syndromeOpen Targets
0.37Weak
Fanconi anemia, complementation group AUniProt
Pathogenic Variants982
NM_000135.4(FANCA):c.3517TGG[1] (p.Trp1174del)Pathogenic
Fanconi anemia|Fanconi anemia complementation group A|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 1174
NM_000135.4(FANCA):c.2639G>A (p.Arg880Gln)Pathogenic
Fanconi anemia complementation group A|Fanconi anemia|not provided|FANCA-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 880
NM_000135.4(FANCA):c.971T>G (p.Leu324Arg)Pathogenic
Fanconi anemia|Fanconi anemia complementation group A|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 324
NM_000135.4(FANCA):c.2852G>A (p.Arg951Gln)Pathogenic
Fanconi anemia|Fanconi anemia complementation group A|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 951
NM_000135.4(FANCA):c.3971C>T (p.Pro1324Leu)Pathogenic
Fanconi anemia complementation group A|not provided|Fanconi anemia
β˜…β˜…β˜†β˜†2026β†’ Residue 1324
NM_000135.4(FANCA):c.1159C>T (p.Gln387Ter)Pathogenic
Fanconi anemia complementation group A|Fanconi anemia
β˜…β˜…β˜†β˜†2026β†’ Residue 387
NM_000135.4(FANCA):c.1A>T (p.Met1Leu)Pathogenic
Fanconi anemia complementation group A|Fanconi anemia
β˜…β˜…β˜†β˜†2026β†’ Residue 1
NM_000135.4(FANCA):c.3349A>G (p.Arg1117Gly)Pathogenic
Fanconi anemia|not provided|Fanconi anemia complementation group A
β˜…β˜…β˜†β˜†2026β†’ Residue 1117
NM_000135.4(FANCA):c.1115_1118del (p.Val372fs)Pathogenic
Fanconi anemia complementation group A|Fanconi anemia|not provided|FANCA-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 372
NM_000135.4(FANCA):c.1074_1075del (p.Tyr359fs)Pathogenic
Fanconi anemia|Fanconi anemia complementation group A|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 359
NM_000135.4(FANCA):c.2641C>T (p.Gln881Ter)Pathogenic
Fanconi anemia|Fanconi anemia complementation group A
β˜…β˜…β˜†β˜†2026β†’ Residue 881
NM_000135.4(FANCA):c.2262_2263del (p.Cys754fs)Pathogenic
Fanconi anemia
β˜…β˜…β˜†β˜†2026β†’ Residue 754
NM_000135.4(FANCA):c.284-2A>CPathogenic
Fanconi anemia|Fanconi anemia complementation group A
β˜…β˜…β˜†β˜†2026
NM_000135.4(FANCA):c.3348+1G>APathogenic
Fanconi anemia complementation group A|not provided|Fanconi anemia|FANCA-related disorder|Colorectal cancer
β˜…β˜…β˜†β˜†2026
NM_000135.4(FANCA):c.893+1G>TPathogenic
Fanconi anemia complementation group A|Fanconi anemia
β˜…β˜…β˜†β˜†2026
NM_000135.4(FANCA):c.2524del (p.Ser842fs)Pathogenic
Fanconi anemia complementation group A|Fanconi anemia
β˜…β˜…β˜†β˜†2026β†’ Residue 842
NM_000135.4(FANCA):c.709+5G>APathogenic
Fanconi anemia|Fanconi anemia complementation group A|not provided
β˜…β˜…β˜†β˜†2026
NM_000135.4(FANCA):c.4198C>T (p.Arg1400Cys)Pathogenic
Fanconi anemia complementation group A|Fanconi anemia
β˜…β˜…β˜†β˜†2026β†’ Residue 1400
NM_000135.4(FANCA):c.1303C>T (p.Arg435Cys)Pathogenic
Fanconi anemia complementation group A|Fanconi anemia|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 435
NM_000135.4(FANCA):c.862G>T (p.Glu288Ter)Pathogenic
not specified|Fanconi anemia|Fanconi anemia complementation group A|not provided|FANCA-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 288
View on ClinVar β†—
Related Genes
SLX4Protein interaction100%CENPSProtein interaction100%FAAP20Protein interaction100%WDR48Protein interaction100%MUS81Protein interaction100%HES1Protein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Brain
17%
Liver
9%
Lung
7%
Ovary
3%
Heart
2%
Gene Interaction Network
Click a node to explore
FANCASLX4CENPSFAAP20WDR48MUS81HES1
PROTEIN STRUCTURE
Preparing viewer…
PDB7KZP Β· 3.10 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.34LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF1.20 [1.08–1.34]
RankingsWhere FANCA stands among ~20K protein-coding genes
  • #1,651of 20,598
    Most Researched238 Β· top 10%
  • #38of 5,498
    Most Pathogenic Variants982 Β· top 1%
  • #14,065of 17,882
    Most Constrained (LOEUF)1.34
Genes detectedFANCA
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Genetics of ovarian insufficiency and defects of folliculogenesis.
PMID: 34794894
Best Pract Res Clin Endocrinol Metab Β· 2022
1.00
2
A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families.
PMID: 29098742
Hum Mutat Β· 2018
0.90
3
Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations.
PMID: 21273304
Blood Β· 2011
0.80
4
Pathogenic mutations identified by a multimodality approach in 117 Japanese Fanconi anemia patients.
PMID: 30792206
Haematologica Β· 2019
0.70
5
The splicing factor CCAR1 regulates the Fanconi anemia/BRCA pathway.
PMID: 39025073
Mol Cell Β· 2024
0.64